vaccine

Novavax, Inc. (NASDAQ: NVAX) shares are trading lower Monday, slightly falling below a pattern the stock has been trading in. On Thursday, the company said it expanded a license agreement for its NVX-CoV2373 recombinant nanoparticle protein-based COVID-19 vaccine with SK Bioscience Co. Novavax...

The year 2021 has featured retail trading-induced short squeezes, soaring special purpose acquisition companies (SPACs) and extreme volatility in cryptocurrency markets. Amid the many bouts of short-term mania, there are a handful of stocks in the S&P 500 Index that...

Key takeaways: Two key legal developments could soon pave the way for a resumption of trading in shares of Nasdaq-listed Sinovac, ending a nearly three-year suspension Company’s revenue may have risen 80-fold or more since the suspension thanks to sales of its globally accepted CoronaVac...

Moderna Inc (NASDAQ: MRNA) shares are trading lower Friday after the company announced interim Phase 1 data for its mRNA flu vaccine. Moderna said mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination for...

Moderna Inc (NASDAQ: MRNA) is having a strong start to the week, up more than 7% Monday on heavy volume. Thus far, the stock has traded over 11 million shares versus its 10 day average of 8 million. What Happened: The stock received positive news late last week as it was granted...

Moderna Inc (NASDAQ: MRNA) shares are trading higher Friday after the FDA authorized its booster dose of COVID-19 vaccine in the U.S. for adults 18 years and older. The company may also be moving on continued momentum after an announcement yesterday stating it filed for authorization of its...

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Tuesday after the FDA removed a hold on the company’s late-stage COVID-19 vaccine trial in the U.S. Inovio Pharmaceuticals is trading up 4.60% at $7.05 at market close Tuesday. Inovio Pharmaceuticals Daily Chart Analysis...

Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday after the company announced its COVID-19 sales came in short of Wall Street analysts estimates by more than $1 billion. The company reported $5 billion in revenue for the third quarter of the year, missing the analyst...

On Tuesday, it became clear that the FDA plans to allow for a “mix and match” approach to vaccine booster shots, allowing—as the Europeans have recommended—people who have been vaccinated against Covid-19 to get a booster shot made from different company than the company...

Moderna Inc (NASDAQ: MRNA) shares traded higher by 2% on Tuesday after U.S. Food and Drug Administration scientists opted not to take a stance on the company’s COVID-19 vaccine booster shot. What Happened: In a new 45-page document, the FDA said data suggests two doses of the Moderna COVID-19...

Moderna Inc. (NASDAQ: MRNA) shares are trading higher Thursday after the company announced plans to build a state-of-the-art mRNA facility in Africa to manufacture up to 500 million doses per year. Moderna's proposed site will also include bottling and packaging capabilities. The company said...

Merck & Co., Inc. (NYSE: MRK) announced last week the oral COVID-19 pill it is co-developing with Ridgeback Biotherapeutics reduces the risk of hospitalization or death by 50%. The announcement triggered an across-the-board, steep sell-off in COVID-19 vaccine stocks. The Merck Analyst: BofA...

Close on heels of the U.S. Food and Drug Administration issuing restricted authorization for the Pfizer Inc. (NYSE: PFE)-BioNTech SE - ADR (NASDAQ: BNTX) COVID-19 booster vaccine dose, it is also expected to greenlight rival vaccine maker Moderna Inc.'s (...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (NASDAQ: XLRN) DexCom, Inc. (NASDAQ: DXCM) Inspire Medical Systems, Inc. (NASDAQ: INSP) Leap Therapeutics, Inc. (NASDAQ:...

Moderna, Inc. (NASDAQ: MRNA) shares are picking up momentum after a steep sell-off on Monday, triggered by a scientific publication that suggested booster doses are unwarranted at this point of time. The company released a statement Wednesday that said incremental data from the Phase 3 COVE...